A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Clinical trial NCT04557462 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04557462
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-20
- Primary completion
- 2030-12-04
- Enrollment
- 448
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.